Anixa is a biotechnology company focused on the treatment and prevention of cancer.
Anixa's therapeutics portfolio consists of a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa’s vaccine portfolio consists of technology focused on the immunization against specific “retired” proteins associated with breast cancer, specifically triple negative breast cancer (TNBC), and ovarian cancer. Further, Anixa is developing additional “retired tissue specific protein” vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. Retired proteins are proteins that are expressed at certain times in life and then are no longer expressed in healthy people.
Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Strong Leadership Backed by Success
Our management team has had many successes, especially in connection with starting, building and investing in technology related companies.
Latest News & Events
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10
Read More...Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Read More...Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Read More...